Using this proof‐of‐concept workflow for identifying interacting proteins of interest, we characterized proteins proximal to p‐Tau in PSP cases, identifying >84% of previously identified interaction partners of Tau and known modifiers of Tau aggregation, while 19 novel proteins not previously found associated with Tau were identified. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.